Posts Tagged ‘antibiotic resistance’



Ingredients of an Effective Antibiotic Stewardship Program: Be Sure to Add Health IT and Medical Device Innovation

June 14th, 2012
Posted by

It is common knowledge that antibiotic resistance is on the rise. For example, infection with resistant Klebsiella pneumoniae carbapenemase (KPC), once found only in North Carolina, now plagues 37 states. While antibiotics are important tools, their overuse results in more antibiotic resistance cases such as KPC. In fact, suboptimal use of antibiotics may be as high as 68% of all applications in healthcare. Some researchers even suggest that overuse may force bacteria to mutate faster, creating an evolutionary trend of ever-increasing rates of antibiotic resistance.
 
Reducing antibiotic use can, in turn, reduce antibiotic resistance rates. Most overuse of antibiotics stems from inadequate instruction about bacterial resistance, improper use of broad-spectrum antibiotics when narrow-spectrum drugs are available, and unnecessarily long durations of treatment.
  Read the rest of this entry »

Tags: , , , , ,
Posted in Our Views | 1 Comment »





Biodegradable Nanostructures – A Novel Means of Combating Antibiotic Resistance

May 10th, 2011
Posted by

Antibiotic resistance: Two words that strike fear in physicians, hospital workers, and patients and which increasingly grab the attention of media outlets throughout the world.
 
Nanotechnology, the branch of engineering that deals with things smaller than 100 nanometers (especially with the manipulation of individual molecules), continues to make inroads in various areas of medicine and life sciences. Over the past several years we have seen advances in nanomaterials that provide the basis for diagnostic tests, improved vehicles for drug delivery, and novel therapeutics. Among those advances, applications related to the development of novel drugs are especially interesting, particularly where hope in the fight against highly drug-resistant bacteria may be offered.  The ability to carefully engineer nanomaterials to specifically interact with biomolecules suggests that further developments in the therapeutic use of nanomaterials are likely to emerge. Engineered nanomaterials that have ideal drug properties – namely, high selectivity (an ability to hit very specific molecular targets), well understood mechanisms of action that provide high efficacy, and limited side effects – are now on the horizon. So the potential for nanomaterials to replace existing biologics, including monoclonal antibodies and recombinant proteins, is a possibility.
  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our Views | No Comments »